Starbucks, Gilead And Ambev Are At 52-Week Lows: Should You Buy The Dip?
Starbucks, Gilead And Ambev Are At 52-Week Lows: Should You Buy The Dip?
Capital market investors often look for entry points, hidden gems, and value bets. Quality stocks trading at or around their 52-week low levels offer one such opportunity window.
资本市场投资者经常寻找切入点、隐藏的宝石和价值下注。交易价格处于或接近52周低点的优质股票提供了这样的机会窗口。
We looked at established companies that, recently, made new 52-week lows. We point readers' attention to three such stocks, with $35 billion market capitalizations. These are: Starbucks Corp (NASDAQ:SBUX), Gilead Sciences (NASDAQ:GILD) and Ambev SA (NYSE:ABEV).
我们研究了最近创下52周新低的老牌公司。我们将读者的注意力引向三只这样的股票，市值为350亿美元。它们是：星巴克公司（纳斯达克股票代码：SBUX）、吉利德科学（纳斯达克股票代码：GILD）和Ambev SA（纽约证券交易所代码：ABEV）。
Starbucks
星巴克
Trading at around $86.83, the coffee franchise's stock could potentially offer a buy-the-dip opportunity. The Seattle-based company's shares command a market cap of over $98 billion on the stock market and sport an average three-month trading volume of 8.49 million.
这家咖啡专营店的股票交易价格约为86.83美元，有可能提供逢低买入的机会。这家总部位于西雅图的公司的股票市场市值超过980亿美元，三个月的平均交易量为849万股。
The stock also offers, to its investors, a dividend yield of 2.63%.
该股还向其投资者提供2.63％的股息收益率。
Wells Fargo, TD Cowen, and TD Cowen released the last three analyst ratings on April 1, April 1, and March 19, 2024, respectively. These ratings suggest an average price target of $102.33 for Starbucks Corp, implying a potential upside of 17.23% based on the assessments of these three analysts.
富国银行、道明考恩和道明考恩分别于2024年4月1日、4月1日和3月19日发布了最近三次分析师评级。这些评级表明，星巴克公司的平均目标股价为102.33美元，根据这三位分析师的评估，这意味着潜在的上涨幅度为17.23％。
Also Read: $100 Invested In This Stock 15 Years Ago Would Be Worth $1,600 Today
另请阅读：15年前投资这只股票的100美元今天的价值为1,600美元
Gilead Sciences
吉利德科学
Trading at around $69.32, this biopharma stock is currently trading about its 52-week lows. The company gained widespread recognition for its development of antiretroviral drugs for the treatment of HIV/AIDS, including medications such as Truvada, Atripla, and Descovy.
该生物制药股票的交易价格约为69.32美元，目前的交易价格约为52周低点。该公司因开发用于治疗艾滋病毒/艾滋病的抗逆转录病毒药物而获得广泛认可，其中包括Truvada、Atripla和Descovy等药物。
Gilead stock offers a robust dividend yield of 4.43%.
吉利德股票的股息收益率强劲，为4.43％。
Wells Fargo, Mizuho, and Truist Securities recently released the last three analyst ratings. These assessments collectively suggest an average price target of $83.33 for Gilead stock.
富国银行、瑞穗和Truist Securities最近发布了最近三个分析师评级。这些评估共同表明，吉利德股票的平均目标股价为83.33美元。
Based on these ratings, there is an implied 20.16% upside potential for the company.
根据这些评级，该公司的上行潜力为20.16％。
Ambev
Ambev
Ambev SA is widely renowned for its portfolio of beer brands, including popular labels such as Skol, Brahma, Antarctica, and Budweiser. Trading at $2.40, Ambev stock is near-about its 52-week low level of $2.36. The stock also offers a juicy dividend yield of 6.26%.
Ambev SA以其啤酒品牌组合而闻名，其中包括Skol、Brahma、南极洲和百威啤酒等热门品牌。Ambev股票的交易价格为2.40美元，接近其52周低点2.36美元。该股还提供6.26％的丰厚股息收益率。
Based on the analysis of the 8 latest analyst ratings, Ambev SA has a consensus price target of $2.2. The most recent ratings were issued by Barclays, Jefferies, and Bernstein on March 4, 2024, Nov. 22, 2023, and May 24, 2023, respectively.
根据对8个最新分析师评级的分析，Ambev SA的共识目标股价为2.2美元。最新的评级分别由巴克莱、杰富瑞和伯恩斯坦于2024年3月4日、2023年11月22日和2023年5月24日发布。
These assessments collectively indicate an average price target of $3.2 for Ambev stock. Consequently, there's an implied 32.51% upside potential for the company based on these three analyst ratings.
这些评估共同表明，Ambev股票的平均目标股价为3.2美元。因此，根据这三个分析师评级，该公司的上行潜力为32.51％。
These findings suggest that these quality stocks may present lucrative investment opportunities, offering potential upside for investors in the coming months.
这些发现表明，这些优质股票可能带来丰厚的投资机会，为投资者在未来几个月内提供潜在的上行空间。